Navigation Links
Dyadic International Launches High Performance Enzyme for Pulp and Paper Industry Using New C1 Production Platform
Date:2/22/2011

JUPITER, Fla., Feb. 22, 2011 /PRNewswire/ -- Dyadic International, Inc. ("Dyadic") (OTC Pink: DYAI), a global biotechnology company focused on the discovery, development, manufacture and sale of enzyme and protein products for the bioenergy, industrial enzyme and biopharmaceutical industries, announced today that it has launched FibreZyme® G200, a next generation, high performance enzyme designed to improve paper quality and improve the economics of various pulp and paper manufacturing processes.

Brian Murdoch, Dyadic's Senior Director Sales & Technical Development stated, "FibreZyme® G200 is a great addition to our product portfolio and provides further evidence of the value-adding capabilities of Dyadic's C1 platform technology. FibreZyme® G200 operates under wide pH and temperature ranges allowing for seamless integration into most pulp and paper manufacturing processes."

Specific attributes of FibreZyme® G200 include the following:

  • Reduces fiber raw material costs and petroleum-derived chemical usages
  • Reduces pulp refining energy requirements
  • Increases paper machine production rates and efficiencies
  • Improves softness in tissue production
  • Enhances pulp drainage rates and reduces paper drying demand
  • Enhances and restores fiber strength and increases inter-fiber bonding through fibrillation

New Production Platform

FibreZyme® G200 is produced using a new variant of Dyadic's patented and proprietary C1 platform technology which Dyadic refers to as the "white strain." Developed through sustained research efforts at Dyadic Netherlands, the white strain produces significantly less background proteins. These changes allow for more efficient and economical industrial scale production of highly targeted enzymes and proteins at greater purity levels.

Richard Jundzil, Dyadic's Vice President Operations stated, "FibreZyme® G200 represents the first product commercialized using the new C1 white strain. We now have in place all the molecular tools, scale-up experience and production processes necessary to support additional timely market introductions of new enzymes identified from the C1 and other genomes. Dyadic intends to utilize the white strain production platform to create a sustainable and more diverse product portfolio. We also intend to express new enzyme and protein targets with our collaborative partners in a variety of industries."

About Dyadic

Dyadic International, Inc. is a global biotechnology company that uses its patented and proprietary technologies to conduct research, development and commercial activities for the discovery, development, manufacture and sale of enzyme and protein products for the bioenergy, industrial enzyme and biopharmaceutical industries.  Please visit Dyadic's website at www.dyadic.com and Dyadic Netherland's website at www.dyadic.nl.

Cautionary Statement for Forward-Looking Statements

Certain statements contained in this press release are forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause Dyadic's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Except as required by law, Dyadic expressly disclaims any intent or obligation to update any forward-looking statements.

For more information about FibreZyme® G200, please visit www.FibreZyme.com.


'/>"/>
SOURCE Dyadic International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Dyadic International Reports 2010 Third Quarter Financial Results
2. Dyadic International to Announce Third Quarter 2010 Financial Results and Hold Conference Call on November 15, 2010
3. Dyadic International Raises $3 Million in Private Placement of Convertible Notes
4. Dyadic International to Announce Second Quarter 2010 Financial Results and Hold Conference Call on August 13, 2010
5. Dyadic International Announces Final Resolution and Dismissal of Stockholder Class Action Lawsuit
6. Dyadic International Engages The Abraham Group as Strategic Advisor
7. Dyadic International to Present at Rodman & Renshaw 6th Annual Global Healthcare Conference
8. Dyadic International Strengthens Management Team
9. Dyadic International Extends Collaboration With The Scripps Research Institute
10. International team of scientists says its high NOON for microwave photons
11. Max Neeman International Initiates Advisory Committee to Advance and Improve the Conduct of Complex Neurological Trials in India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... ... April 20, 2017 , ... Open Therapeutics and ... (IP) sharing and commercialization model. , The Center for Advancing Innovation helps institutions ... this effort is bringing the IP to the attention of the entrepreneurial community ...
(Date:4/19/2017)... (PRWEB) , ... April 18, 2017 , ... ... 1970s and has been a key device for generating monodisperse droplets of known ... droplet processes and for generating monodisperse solid particles by drying monodisperse droplets. ...
(Date:4/19/2017)... ... April 19, 2017 , ... Nobilis Therapeutics ... Company Seeks to Leverage Clinical Data in its Upcoming Post Traumatic Stress Disorder Trial ... an 81 patient clinical trial assessing efficacy of its NBTX-001, a xenon-based therapeutic in ...
(Date:4/19/2017)... 19, 2017 A new report published by Allied Market ... ," the global market was valued at $6,769 million in 2015, and is ... 2016 to 2022. ... Allied Market Research Logo ...      (Logo: http://photos.prnewswire.com/prnh/20140911/647229) The cross-flow segment ...
Breaking Biology Technology:
(Date:4/19/2017)... April 19, 2017 The global ... landscape is marked by the presence of several large ... held by five major players - 3M Cogent, NEC ... accounted for nearly 61% of the global military biometric ... in the global military biometrics market boast global presence, ...
(Date:4/11/2017)... BEACH GARDENS, Fla. , April 11, 2017 ... identity management and secure authentication solutions, today announced ... contract by Intelligence Advanced Research Projects Activity (IARPA) ... for IARPA,s Thor program. "Innovation has ... onset and IARPA,s Thor program will allow us ...
(Date:4/5/2017)... 5, 2017  The Allen Institute for Cell Science ... a one-of-a-kind portal and dynamic digital window into the ... the first application of deep learning to create predictive ... lines and a growing suite of powerful tools. The ... and future publicly available resources created and shared by ...
Breaking Biology News(10 mins):